Eight Titles, Nine Months and an Incomplete Balance Sheet: Auditing the Super-Shoe Market

2 November 2026. The New York City Marathon elite race is barely finished when the broadcast camera leaves the timing clock and settles on a shoe. The athlete's finger crosses the line, and the screen's first act of identification belongs to the footwear. That evening a sentence goes out from Adidas: eight World Marathon Major titles in 2026. It is true. It is also incomplete.

My ledger says something else. Before New York, six Majors had been run in 2026 — Tokyo, Boston, London, Sydney, Berlin, Chicago. Two titles per Major, men's and women's, makes twelve slots. Eight titles out of twelve is 67 per cent. Nike's highest mark is 2026: ten of twelve across six Majors, 83 per cent. The percentage is my calculation, not the company's release. On the day the company publishes its own counting method, I will move the number into my sheet. Until then, the eight-title poster says one thing and hides another — how many out of twelve.

The receipts were never in the highlights; they were in the price ledger.

2026 to 2026: how the market was built

What Nike opened with the Vaporfly in 2026 was not a shoe. It was a platform. The carbon plate and the foam rewrote the language of selling: a marathon market that once ran on an athlete's story began running on a materials-science claim. That platform bought Nike ten of twelve golds across six Majors and roughly three years of framing the category on its own terms.

The economic base of that market is not the elite. London split its race across two days, New York drew around 250,000 applicants, a record turnout was expected, and the industry itself is describing a participation heyday. That demand comes from habit, not advertising. But it has a condition companies rarely foreground: the entry price sits in the hundreds of dollars. Participation-driven growth is durable, and it is also entirely exposed to consumer discretionary spending.

On the Adidas side, 2026 brought a fundamental reshaping of the development process. That date did not arrive alone: it coincides with the leadership transition and turnaround programme being discussed inside the company. For me that is the necessary signal — this was a management-driven reform, not a bottom-up engineering experiment. Such reforms move fast and can also be cut fast, because they have to be saved every quarter.

Football enters this conversation in exactly one place, and it is marketing, not engineering. Adidas executive Patrick Nava himself drew the contrast: football sells through clubs and leagues as properties, running sells through individual athletes and mass participation. That changes the KPI. In football you cannot buy the league; in running you can buy a person and a shoe. Which is why this market's real contest is fought over contracts and calendars, not over a pitch.

Nine months against eighteen

Adidas's elite Evo line was developed in nine months. The industry norm is put at 18 to 24. The figure is the company's, independently unverified, and I read it the way I read any club statement about academy investment — the direction may be right, the number is still a statement. If the direction holds, though, it is the most important figure in this market, because it is not a product. It is a calendar.

Copying a shoe takes a season. Copying a calendar takes a hiring programme. And a hiring programme is the last thing to be cut, or the first. Adidas has more than a hundred people in running-shoe innovation, against a few dozen some years ago. Headcount is the rare number marketing cannot spin: heads can be counted. And a nine-month cycle implies athletes are co-developers, not endorsers — testing, refining, redeveloping, continuously. That is organisational capability, and organisational capability outlasts a product.

This is where an old habit kicks in. I rewatched the last five kilometres in New York twice at 0.5x — once to watch the shoes, once to forget them. What breaks in the final two kilometres is not the foam. It is the pacing. The chase pack's form drops, cadence frays, and that decline is set by the week's training load, not by the day's retail price. I rewatched the tape until cadence became a paper trail, and the tape does not do PR. A shoe appears somewhere across 42 kilometres. It does not appear in the last two.

So when a company says wins prove innovation, I ask a different question: how much of the win is engineering, and how much is recruitment?

The academy nobody calls an academy

Adidas's second running strategy gets less attention: talent recruitment through a coach, expert and athlete network, starting as early as the youth level. I call it an academy for endorsement rights. The economics are simple. Buying before the peak is cheaper than bidding at it.

Benson Kipruto is the cleanest case. Adidas signed him after he finished second on his marathon debut in Athens around a decade ago, when his market value sat below his career value. The ledger after that is public: Chicago 2026, Tokyo 2026, Olympic bronze at Paris 2026, and a title defence in New York. That is buy-low, develop-high.

Now bolt that onto the cost side. The industry concedes that the cost of even competing in this space keeps rising. When inputs inflate, the pipeline becomes insurance — instead of standing in an auction at the top, you build a supply line. This is my thesis, flagged as such, not a finding: if bidding for top athletes jumps over the next two seasons, the brands with youth-level scouting absorb it best. I keep it on a watchlist, not in the evidence file.

A win is a KPI, not proof

The internal belief is that wins measure innovation. It is the weakest measure available. First, wins do not separate product quality from roster quality. Second, course profile, pacing dynamics and race-day variance all collapse into one outcome. Third, and most important, if the company is scouting talent at youth level, an unknown share of the win delta is talent identification, not engineering. You cannot use your own scouting network as proof of your own product.

The fourth problem is arithmetic, and this is where the ledger speaks loudest. Sydney joined in 2026, taking the Majors from six to seven. Annual title slots rose from twelve to fourteen. In the year your win count rises, so does your room to lose. Comparing eight titles to Nike's 2026 requires a like-for-like denominator, and no company is supplying one.

Two companies, two units

Here my complaint stops being about any one brand winning. Adidas says running revenue rose 19 per cent year on year in Q3, inside a record-breaking quarter. That is a rate. Nike says running has grown at a double-digit pace for six consecutive quarters, and that its share of max-cushion nearly tripled. That is a streak and a share.

Neither discloses absolute running revenue. One gives a single quarter's percentage; the other gives the length of a run. These are different units, and different units are not comparable. When two companies deliberately report in different units, that is not transparency. That is a hedge wearing transparency as a coat.

Notice who is hiding what. Adidas's 19 per cent does not say what share of group revenue running represents; a fast-looking percentage on a small showpiece category is still a small category. Nike's six-quarter streak looks strong because it is a line rather than a point — but the base size is undisclosed too. Each company is presenting its number in the shape that flatters it most.

Nike's real problem in this picture is not engineering. Full-year revenue is forecast to fall steeply, restructuring is under way, jobs are being cut and divisions reshuffled. Restructuring cuts first the thing that does not show up in the quarterly number — innovation headcount. The same company has publicly said it will innovate at a pace nobody has seen. Both statements belong to one company. Read them together, not separately.

What the critics miss

The popular reading is that Adidas has won the super-shoe war because it has eight titles and Nike has excuses. I find that reading incomplete, for three reasons.

One: if the advantage is process, it is more fragile than any product. A nine-month cycle rests on more than a hundred heads. In a downturn, those heads get counted first. Product quality can survive a season. A calendar cannot.

Two, and I will say it plainly: Nike's six-quarter streak is a better demand signal than Adidas's single 19 per cent quarter — provided the bases match, which we do not know. That is why I leave both claims unresolved rather than crowning one and burying the other.

Three, and this is what gets lost while writing in a contrarian mood: what is genuinely working deserves the same evidentiary standard. London splitting its race over two days and New York's 250,000 applicants are not PR. They are demand documents. Participation-driven growth is more durable than share-swapping, because it arrives on new feet rather than in new adverts. An empty stadium still has a balance sheet, and somebody always pays the difference — here, the consumer buying a shoe priced in the hundreds.

What the critics miss most is that the real risk in this contest belongs to neither brand but to the whole category. Growth built on a several-hundred-dollar price point can fold on a small hesitation in discretionary spending. If that hesitation arrives, what shoe is fastest becomes a moot question for two years.

What to watch next

Over the next four quarters I will watch three things, and all three live in filings, not press releases.

One: whether Adidas breaks out absolute running revenue, or whether the 19 per cent keeps circulating instead. A growth rate is easy to publish; a size is hard.

Two: whether Nike's restructuring touches its innovation headcount. If it does, the pace-nobody-has-seen line will turn up on a different company's poster next year.

Three: whether the nine-month cycle survives the next rule change. Regulation is the one thing that can wipe out a calendar's entire saving in a single morning.

And the next time a brand prints an eight-title poster, ask one question. Out of twelve — how many? And who took the other four?